Ha habido 50 transacciones internas recientes registradas para InMed Pharmaceuticals Inc. (INM), incluyendo 31 compras y 2 ventas. El total de compras internas fue valorado en $392.96K y el total de ventas internas en $18.54K.
Internos destacados con actividad reciente incluyen Klompas Neil A, Hsu Eric C, Adams Eric A. Las transacciones internas pueden proporcionar información sobre cómo la dirección de la empresa ve la valoración y perspectivas futuras de la acción.
Operaciones de Insiders — INM
| Fecha |
Nombre |
Cargo |
Tipo de Transacción |
Acciones |
Precio Promedio |
Valor |
Acciones en Propiedad |
| 2025-12-19 |
Klompas Neil A |
Director |
Concesión de RSU |
1,750 |
$1.29 |
$2.26K |
5,250 |
| 2025-12-19 |
Hsu Eric C |
Sr. VP, Pre-clinical Res/dev |
Concesión de RSU |
13,000 |
$1.29 |
$16.77K |
18,280 |
| 2025-12-19 |
Adams Eric A |
President & CEO |
Concesión de RSU |
35,000 |
$1.29 |
$45.15K |
49,050 |
| 2025-12-19 |
Woudenberg Michael |
Chief Operating Officer |
Concesión de RSU |
18,000 |
$1.29 |
$23.22K |
25,445 |
| 2025-12-19 |
Hull Andrew |
Director |
Concesión de RSU |
1,750 |
$1.29 |
$2.26K |
2,711 |
| 2025-12-19 |
Johnson Shane Aaron |
Sr VP & General Manager |
Concesión de RSU |
8,500 |
$1.29 |
$10.97K |
12,400 |
| 2025-12-19 |
Lemerond Nicole |
Director |
Concesión de RSU |
1,750 |
$1.29 |
$2.26K |
2,725 |
| 2025-12-19 |
Jagpal Netta |
Chief Financial Officer |
Concesión de RSU |
18,000 |
$1.29 |
$23.22K |
24,250 |
| 2025-12-19 |
Bathery John Steven |
Director |
Concesión de RSU |
1,750 |
$1.29 |
$2.26K |
5,250 |
| 2025-12-15 |
Hsu Eric C |
Sr. VP, Pre-clinical Res/dev |
Opción Expirada |
70 |
$1,397.97 |
$97.86K |
5,280 |
| 2025-12-15 |
Adams Eric A |
President & CEO |
Opción Expirada |
250 |
$1,397.97 |
$349.49K |
14,050 |
| 2025-12-15 |
Woudenberg Michael |
Chief Operating Officer |
Opción Expirada |
60 |
$1,397.97 |
$83.88K |
7,445 |
| 2025-12-15 |
Hull Andrew |
Director |
Opción Expirada |
14 |
$1,397.97 |
$19.57K |
961 |
| 2025-10-17 |
Klompas Neil A |
Director |
Concesión de RSU |
3,500 |
$2.10 |
$7.35K |
3,500 |
| 2025-10-14 |
Bathery John Steven |
Director |
Desconocido |
3,500 |
$2.10 |
$7.35K |
- |
| 2025-01-11 |
Hull Andrew |
Director |
Opción Expirada |
2 |
$2,860.21 |
$5.72K |
975 |
| 2024-12-20 |
Grove Janet P |
Director |
Concesión de RSU |
550 |
$4.14 |
$2.28K |
975 |
| 2024-12-20 |
Baldasare Bryan T |
Director |
Concesión de RSU |
550 |
$4.14 |
$2.28K |
975 |
| 2024-12-20 |
Hsu Eric C |
Sr. VP, Pre-clinical Res/dev |
Concesión de RSU |
2,750 |
$4.14 |
$11.39K |
5,350 |
| 2024-12-20 |
Adams Eric A |
President & CEO |
Concesión de RSU |
6,250 |
$4.14 |
$25.88K |
14,300 |
| 2024-12-20 |
Woudenberg Michael |
Chief Operating Officer |
Concesión de RSU |
3,750 |
$4.14 |
$15.53K |
7,505 |
| 2024-12-20 |
Hull Andrew |
Director |
Concesión de RSU |
550 |
$4.14 |
$2.28K |
977 |
| 2024-12-20 |
Johnson Shane Aaron |
Sr VP & General Manager |
Concesión de RSU |
1,500 |
$4.14 |
$6.21K |
3,900 |
| 2024-12-20 |
Lemerond Nicole |
Director |
Concesión de RSU |
550 |
$4.14 |
$2.28K |
975 |
| 2024-12-20 |
Jagpal Netta |
Chief Financial Officer |
Concesión de RSU |
3,750 |
$4.14 |
$15.53K |
6,250 |
| 2024-10-09 |
Klompas Neil A |
Director |
Desconocido |
- |
- |
- |
- |
| 2024-07-31 |
Mancini Alexandra Diane Janet |
Other: Consultant |
Venta Informativa |
240 |
$0.18 |
$42.31 |
- |
| 2024-05-27 |
Hsu Eric C |
Sr. VP, Pre-clinical Res/dev |
Opción Expirada |
545 |
$263.18 |
$143.43K |
52,000 |
| 2024-05-27 |
Adams Eric A |
President & CEO |
Opción Expirada |
1,139 |
$263.18 |
$299.76K |
161,000 |
| 2024-05-27 |
Woudenberg Michael |
Chief Operating Officer |
Opción Expirada |
394 |
$263.18 |
$103.69K |
75,100 |
| 2024-03-04 |
Hsu Eric C |
Sr. VP, Pre-clinical Res/dev |
Opción Expirada |
309 |
$364.72 |
$112.7K |
52,545 |
| 2024-02-21 |
Hull Andrew |
Director |
Compra Informativa |
37,500 |
$0.39 |
$14.63K |
38,258 |
| 2024-02-20 |
Adams Eric A |
President & CEO |
Compra Informativa |
41,600 |
$0.36 |
$14.92K |
43,959 |
| 2024-02-20 |
Jagpal Netta |
Chief Financial Officer |
Disposición |
50,000 |
$0.37 |
$18.5K |
- |
| 2024-01-21 |
Mancini Alexandra Diane Janet |
Sr VP, Clinical Reg Affairs |
Opción Expirada |
121 |
$312.73 |
$37.84K |
52,485 |
| 2024-01-14 |
Hull Andrew |
Director |
Opción Expirada |
42 |
$307.01 |
$12.89K |
8,542 |
| 2023-12-23 |
Grove Janet P |
Director |
Concesión de RSU |
7,100 |
$0.37 |
$2.63K |
8,500 |
| 2023-12-23 |
Tegge Jonathan |
Interim CFO |
Concesión de RSU |
30,000 |
$0.37 |
$11.1K |
31,400 |
| 2023-12-23 |
Baldasare Bryan T |
Director |
Concesión de RSU |
7,100 |
$0.37 |
$2.63K |
8,500 |
| 2023-12-23 |
Hsu Eric C |
Sr. VP, Pre-clinical Res/dev |
Concesión de RSU |
45,000 |
$0.37 |
$16.65K |
52,854 |
| 2023-12-23 |
Adams Eric A |
President & CEO |
Concesión de RSU |
136,000 |
$0.37 |
$50.32K |
162,139 |
| 2023-12-23 |
Woudenberg Michael |
Chief Operating Officer |
Concesión de RSU |
65,000 |
$0.37 |
$24.05K |
75,494 |
| 2023-12-23 |
Mancini Alexandra Diane Janet |
Sr VP, Clinical Reg Affairs |
Concesión de RSU |
45,000 |
$0.37 |
$16.65K |
52,606 |
| 2023-12-23 |
Hull Andrew |
Director |
Concesión de RSU |
7,100 |
$0.37 |
$2.63K |
8,584 |
| 2023-12-23 |
Johnson Shane Aaron |
Sr VP & General Manager |
Concesión de RSU |
40,000 |
$0.37 |
$14.8K |
48,000 |
| 2023-12-23 |
Lemerond Nicole |
Director |
Concesión de RSU |
7,100 |
$0.37 |
$2.63K |
8,500 |
| 2023-12-05 |
Woudenberg Michael |
Chief Operating Officer |
Opción Expirada |
848 |
$270.36 |
$229.27K |
10,494 |
| 2023-08-31 |
Hsu Eric C |
Sr. VP, Pre-clinical Res/dev |
Opción Expirada |
327 |
$499.96 |
$163.49K |
7,854 |
| 2023-05-16 |
Hsu Eric C |
Sr. VP, Pre-clinical Res/dev |
Opción Expirada |
152 |
$623.93 |
$94.84K |
8,181 |
| 2023-05-16 |
Adams Eric A |
President & CEO |
Opción Expirada |
1,818 |
$623.93 |
$1.13M |
26,139 |
■ Informativa — transacción en mercado abierto (más significativa)
■ No informativa (compra) — premio, ejercicio de opción, conversión
■ No informativa (venta) — retención fiscal, venta de adjudicación
■ Neutral — regalo, fideicomiso, vencimiento
